Cranberry fruit powder (Flowens™) improves lower urinary tract symptoms in men: a double-blind, randomized, placebo-controlled study
Language English Country Germany Media print-electronic
Document type Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
PubMed
26049866
DOI
10.1007/s00345-015-1611-7
PII: 10.1007/s00345-015-1611-7
Knihovny.cz E-resources
- Keywords
- Benign prostatic hyperplasia, Cranberry, IPSS, Lower urinary tract symptoms, Vaccinium macrocarpon,
- MeSH
- Time Factors MeSH
- Double-Blind Method MeSH
- Phytotherapy methods MeSH
- Prostatic Hyperplasia complications physiopathology therapy MeSH
- Middle Aged MeSH
- Humans MeSH
- Urination physiology MeSH
- Follow-Up Studies MeSH
- Fruit * MeSH
- Powders therapeutic use MeSH
- Lower Urinary Tract Symptoms etiology physiopathology therapy MeSH
- Vaccinium macrocarpon * MeSH
- Treatment Outcome MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Randomized Controlled Trial MeSH
- Names of Substances
- Powders MeSH
BACKGROUND: Lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia increase with age. To date, several medications are available to treat LUTS, including herbal remedies which offer less side effects but lack robust efficacy studies. METHODS: This 6-month, randomized, double-blind, placebo-controlled study aimed at evaluating the dose effect of 250 or 500 mg cranberry powder (Flowens™) on LUTS and uroflowmetry in men over the age of 45. A total of 124 volunteers with PSA levels <2.5 ng/mL and an international prostate symptoms score (IPSS) score ≥8 were recruited and randomized. The primary outcome measure was the IPSS, evaluated at 3 and 6 months. Secondary outcome measures included quality of life, bladder volume (Vol), maximum urinary flow rate (Q max), average urinary flow rate (Q ave), ultrasound-estimated post-void residual urine volume (PVR), serum prostate-specific antigen, selenium, interleukin 6, and C-reactive protein at 6 months. RESULTS: After 6 months, subjects in both Flowens™ groups had a lower IPSS (-3.1 and -4.1 in the 250- and 500-mg groups, p = 0.05 and p < 0.001, respectively) versus the placebo group (-1.5), and a dose-response effect was observed. There were significant differences in Q max, Q ave, PVR, and Vol in the Flowens™ 500-mg group versus baseline (p < 0.05). A dose-dependent effect on Vol was observed, as well as on PVR, for participants with a nonzero PVR. There was no effect on clinical chemistry or hematology markers. CONCLUSIONS: Flowens™ showed a clinically relevant, dose-dependent, and significant reduction in LUTS in men over 45.
Department of Urology University Hospital Olomouc Czech Republic
See more in PubMed
Am J Manag Care. 2006 Apr;12(5 Suppl):S122-8 PubMed
Adv Nutr. 2013 Nov 06;4(6):618-32 PubMed
Ther Adv Urol. 2012 Apr;4(2):77-83 PubMed
Phytomedicine. 2007 Aug;14(7-8):568-79 PubMed
Eur Urol. 2010 Oct;58(4):616-25 PubMed
Neurourol Urodyn. 2002;21(3):261-74 PubMed
Prostate. 2004 Sep 15;61(1):60-72 PubMed
J Pharmacol Sci. 2010;112(2):121-7 PubMed
Neurourol Urodyn. 2013 Mar;32(3):261-5 PubMed
Br J Urol. 1981 Dec;53(6):613-6 PubMed
Andrologia. 2012 May;44 Suppl 1:396-409 PubMed
Indian J Urol. 2007 Apr;23(2):114-8 PubMed
Eur Urol. 2007 May;51(5):1202-16 PubMed
J Urol. 1999 Jan;161(1):122-7 PubMed
Nutr Res Pract. 2011 Oct;5(5):404-11 PubMed
Cochrane Database Syst Rev. 2009 Apr 15;(2):CD001423 PubMed
Cochrane Database Syst Rev. 2000;(2):CD001043 PubMed
N Engl J Med. 2012 Jul 19;367(3):248-57 PubMed
Crit Rev Food Sci Nutr. 2009 Oct;49(9):741-81 PubMed
Br J Nutr. 2010 Oct;104(8):1181-9 PubMed
J Urol. 2008 Jul;180(1):47-54 PubMed
Curr Urol Rep. 2013 Dec;14 (6):606-13 PubMed
